Colombian-based Khiron Life Sciences is a global cannabis company that has developed a reputation as a Latin American industry leader. In March 2020, Khiron made history by becoming the first company to develop and commercialize a medical cannabis product in Colombia. Since then, the company has achieved many other milestones to empower its place in the global cannabis industry.
CEO Alvaro Torres and VP of Business Development Andrés Galofre launched Khiron in 2017 with a focused mission to improve people’s quality of life, change how medical cannabis products were seen and present their application as an effective treatment option for common health conditions such as anxiety and chronic pain, as well as more specific illnesses including Parkinson’s disease and epilepsy.
With core operations in Latin America, along with activity in North America and Europe, Khiron continues to be a leader in the development of medical cannabis in a highly regulated industry across Latin America. This is largely due to their “seed to patient” operation, which serves as a source for research, development and innovative health models.
“The medical cannabis industry is still in its formative years in Colombia and across Latin America,” Torres said. “Regulatory protocols are expected to evolve and with firms such as Khiron leading the path forward on issues from compliance to innovation, the region will undoubtedly play a pivotal role as the multi-billion global cannabis industry matures.”
Read more at cannabisnow.com